1 min read
Ideaya Plans IDE849 Cohort for About 90 Patients With Neuroendocrine Cancer
The planned single-arm extension would enroll previously treated patients with gastroenteropancreatic neuroendocrine carcinoma in an ongoing Phase 1/2 study.

Ideaya Biosciences plans to begin a single-arm extension cohort of about 90 previously treated patients in its ongoing Phase 1/2 trial of IDE849 for gastroenteropancreatic neuroendocrine carcinoma.
The cohort is part of Ideaya’s registrational strategy for IDE849 in neuroendocrine carcinomas.